| Literature DB >> 25455505 |
Elisa Borsò1, Giuseppe Boni2, Sara Mazzarri2, Ardico Cocciaro3, Carlo Gambacciani3, Antonio C Traino4, Giampiero Manca2, Mariano Grosso2, Cristian Scatena5, Valerio Ortenzi5, Riccardo Vannozzi3, Maria Cristina Marzola6, Domenico Rubello6, Giuliano Mariani2.
Abstract
In this paper we report on a successful management of multiple bone metastases from differentiated thyroid cancer. In 2007, a 75-year-old female patient, previously referred for thyroidectomy for multinodular goiter, underwent surgical removal of a lumbar mass with histological findings of metastasis from well differentiated thyroid cancer. After surgery, serum thyroglobulin (sTg) was 204.4 ng/mL. A diagnostic/dosimetric (123)I WBS was performed, following stimulation by rTSH. Serial WBSs were acquired, along with SPECT/CT and bone scan for localization of lesions. sTg raised to 3.810 ng/mL, and (123)I WBS showed thyroid remnants and numerous areas with high iodine-uptake corresponding to skeletal sites, the two largest loading on the skull, with osteolytic pattern. Calculated radiation absorbed dose for skull lesions, determined by mean of MIRD methodology, was 63.5 mGy/MBq. The patient underwent surgical removal of the two major skull lesions. Successively, 100 mCi (131)I was administered after stimulation by rTSH, with stimulated sTg 297 ng/mL. After 8 months, diagnostic WBS was negative both for remnants and metastases and rTSH-stimulated Tg was 0.6 ng/mL. To date, the patient has maintained sTg values <1 ng/mL during L-T4 suppressive therapy and after rTSH stimulations. In this unusual case of extensive bone cancerous involvement with high iodine avidity, a multidisciplinary approach based on surgery and dosimetry-guided radiometabolic therapy allowed to accurately assess the patient, execute a small number of treatments and achieve a complete remission of the disease in a very short time, with no additive morbidity.Entities:
Keywords: Bone metastases; Cirugía; Dosimetry; Dosimetría; Metástasis ósea; Surgery; Thyroid; Tiroides; rTSH
Mesh:
Substances:
Year: 2014 PMID: 25455505 DOI: 10.1016/j.remn.2014.09.004
Source DB: PubMed Journal: Rev Esp Med Nucl Imagen Mol ISSN: 2253-654X Impact factor: 1.359